" class="no-js "lang="en-US"> Tridek-One SAS - Medtech Alert
Friday, August 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tridek-One SAS | Pharmtech Focus

Tridek-One SAS

About Tridek-One SAS

Tridek-One SAS

Tridek-One is a private biotechnology company formed out of INSERM (Paris, France), and backed by a strong group of international investors that includes Pureos Bioventures, AdBio partners, Bpifrance, Advent Life Sciences and Bioqube Ventures. The company develops first-in-class immune checkpoint agonists to restore the immune balance in patients living with auto-immune diseases.
Created in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti and based in Paris, France, Tridek-One raised €3M ($3.02M) in 2019 in a first funding round supported by two venture funds, AdBio partners and Advent Life Sciences.

Related Story

Diseases

 Tridek-one Closes a €16 Million Financing Round to Develop First-in-class Immune Checkpoint Agonists | Pharmtech Focus

Tridek-one Closes a €16 Million Financing Round to Develop First-in-class Immune Checkpoint Agonists

September 16 2022

Tridek-One SAS (the ‘Company’), a leading biotech start-up specialized in the research and development of […]